Piper Sandler analyst Christopher Raymond downgraded Oncorus to Neutral from Overweight with a price target of $2, down from $6. With today’s decision to pull the plug on lead program ONCR-177, Oncorus’s next program, ONCR-021, is about a year from the clinic, Raymond tells investors in a research note. And even with the announced restructuring, the company’s cash balance could become a concern before any clinical data from ONCR-021, says the analyst. "With this set-up we are hard-pressed to articulate a bull thesis at this point," writes Raymond.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ONCR:
- Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer
- Oncorus announces reprioritization of lead product candidate ONCR-021
- Oncorus to Participate in Upcoming Investor Conferences
- Oncorus Presents Preclinical Data Supporting ONCR-719, an armed HSV-1 Vector engineered to use the Epidermal Growth Factor Receptor (EGFR/EGFRvIII) for viral entry in Glioblastoma, at the 2022 Society for Neuro-Oncology Annual Meeting
- Oncorus Announces Publication in Nature Communications Highlighting the Development of its Intravenously Administered Synthetic vRNA/LNP Platform for the Treatment of Cancer
